Pfizer Inc. Stock
€22.63
Your prediction
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Not a member yet? Sign up for free!
Financial data and news for Pfizer
sharewise wants to provide you with the best news and tools for Pfizer, so we directly link to the best financial data sources.
Financials
News
Pfizer Pops on Q4 Results—But This May Be the Catalyst That Matters Most
Pfizer Inc. (NYSE: PFE) helped boost the Dow Jones Industrial Average (DJIA) the day after delivering a double beat in its fourth-quarter earnings report.
Revenue of $17.56 billion topped
Ozempic, Mounjaro, Wegovy, or Zepbound? This ETF Holds Them All
After a lackluster first half of 2025, healthcare stocks staged a comeback, posting the best performance among the 11 S&P 500 sectors over the past six months.
In large part, that rebound was
This ETF Is Proof That the Healthcare Rebound Is Real
With well-publicized losses for companies including UnitedHealth Group (NYSE: UNH), Elevance Health (NYSE: ELV), and Wegovy and Ozempic maker Novo Nordisk (NYSE: NVO), the healthcare sector failed
These 3 Stocks Trade at Discounts the Market Won’t Ignore Forever
The S&P 500 wrapped up 2025 with a total return of about 18%, the third straight year above historical norms but a lower figure than the gangbusters 25% returns of 2023 and 2024. AI euphoria is
Why Wall Street Gave Up on Pfizer—and Why That May Be a Mistake
The market of 2025 will be remembered for its extremes. While investors poured billions into technology sector giants and companies manufacturing weight-loss drugs, traditional pharmaceutical
Pfizer Adds to Its Big Bet on Weight Loss Drugs
Health care stocks have been on a run lately, leading the S&P 500’s 11 sectors over the past three months with a gain of 11.55%. Unfortunately for some investors, that recent rally has not
HIMS Has Been a Roller Coaster Ride. Should Investors Hop On?
Most of the health care sector's headlines are dominated by Big Pharma giants. Legacy companies, including AbbVie (NYSE: ABBV), Eli Lilly (NYSE: LLY), Pfizer (NYSE: PFE), and Merck (NYSE: MRK)—and
5 Healthcare Plays Powering the Sector’s Big Comeback
After years of underperformance, the healthcare sector may finally be waking up. The Health Care Select Sector SPDR Fund (NYSEARCA: XLV), which tracks the largest U.S. healthcare companies, has
Why AbbVie and Johnson & Johnson Could Outperform Pfizer
Pfizer Inc. (NYSE: PFE) made a strong move higher after it became the first drug manufacturer to sign on as part of the TrumpRx platform. PFE stock is up nearly 14% since its closing price of
TrumpRx Brings Pfizer Into the Green—Is It a Buy?
Pfizer (NYSE: PFE) is no stranger to income investors. The drugmaker, famous for treatments including Lipitor, Viagra, and Zoloft, has now increased its dividend payout for 16 consecutive years
Eli Lilly Stock Soars on Trump Tariff Hopes and Pfizer Deal
After tanking in early August, the world’s most valuable pharmaceutical stock has roared back with a vengeance. That firm is Eli Lilly and Company (NYSE: LLY), the maker of the wildly popular
Trump’s Drug Price Cuts: Boom or Bust for These 3 Pharma Giants
When investors hear that a company will lower prices on its products, their instinctive reaction is to expect a sequential decline in margins and profits, which is not entirely incorrect. However
Pfizer is Locking in New Growth Through a New Acquisition
In the United States' healthcare sector, a new growth theme is emerging that nearly all companies want to capitalize on. Like artificial intelligence for technology stocks, weight loss drug
Is Pfizer Stock an Underrated Healthcare Investment Play?
Pharmaceutical giant Pfizer (NYSE: PFE) recently had to drop its internally developed GLP-1 weight loss drug candidate. The unfortunate outcome is that the company has had to watch rivals Novo
Is Pfizer Stock the Only Big Pharma Name I'd Buy and Hold Through Any Market Crash?
Pfizer (NYSE: PFE) is the name behind one of the world's top-selling products: the coronavirus vaccine. It brought in more than $37 billion at its peak in 2022 and helped the company achieve $100
1 Reason I'd Buy Eli Lilly Stock and Never Sell
Investing in pharmaceutical stocks can be tricky. Drugmakers put an enormous amount of time and money into research and development of new products. It takes more than 10 years to develop a new drug
What Is One of the Best Pharmaceutical Stocks to Own for the Next 10 Years?
The pharmaceutical industry can be a tricky investment.
Remember Pfizer (NYSE: PFE) back in 2020? Its stock price shot from around $33 in February 2020 to nearly $60 by December due to its rapid
Meet the 6.3% Yield Dividend Stock That Could Soar in 2026
Pfizer (NYSE: PFE) has a well-above-market dividend yield of 6.3%. Despite a payout ratio that is over 100%, the drugmaker states that it plans to maintain the dividend. But the real catalyst for a
Is Now the Best Time to Buy Pfizer Stock?
Pfizer (NYSE: PFE) recently experienced yet another setback. The drugmaker has been posting disappointing financial results for several years, and its latest quarterly update sent its stock price
Healthcare Stocks Are Sinking. Here Are 2 to Buy on the Dip.
There are almost always some companies doing well, even when competitors in the same industry are sinking. Right now, investor enthusiasm has GLP-1 weight loss drug leader Eli Lilly (NYSE: LLY)
Should You Buy Pfizer's Stock for Its 6.3%-Yielding Dividend?
Pfizer (NYSE: PFE) has been an underwhelming stock to own in recent years. Question marks about its growth and how it will do in the future, as it faces multiple patent cliffs, have resulted in
3 Healthcare Stocks Paying the Highest Dividends of 2026
With healthcare's status as a recession-resistant industry, healthcare stocks can be a great place for dividend investors to find companies paying out steady, consistent dividends. However, it's not
Can Pfizer Crash the Lilly and Novo Nordisk Weight-Loss Party?
Eli Lilly's (NYSE: LLY) obesity drug, Zepbound, generated sales of $13.5 billion in 2025. Its Type 2 diabetes drug Mounjaro, which is also marketed for treating obesity outside of the U.S., Canada
Eli Lilly Soared by 39% in 2025, but Here's Another Healthcare Stock to Buy in 2026
Eli Lilly's (NYSE: LLY) share price jumped 39% in 2025, driven by investors eager to benefit from the success of the company's GLP-1 drugs, Mounjaro (for diabetes) and Zepbound (for weight loss)
Why 2026 Could Be the Year Pfizer's Stock Finally Takes Off
Shares of pharmaceutical giant Pfizer (NYSE: PFE) have been crashing for multiple years. The last time it posted a positive gain was in 2021, when it rose by more than 60%. Back then, business was